inflammatory diseases
NICE backs Novartis’ Cosentyx for underdiagnosed back condition
Phil Taylor
axial spondyloarthritis, Cosentyx, HEOR, inflammatory diseases, NICE, Novartis
0 Comment
Alvotech files lawsuit challenging AbbVie’s Humira patent thicket
Richard Staines
AbbVie, Alvotech, biosimilars, Humira, inflammatory diseases, patent
0 Comment
Sanofi licences in potential oral IL-17 drug from UK’s C4X Discovery
Richard Staines
Biotech, C4XD, inflammatory diseases, psoriasis, Sanofi
0 Comment
Amgen buys inflammatory diseases drug firm Rodeo for up to $721m
Richard Staines
Amgen, inflammatory diseases, M&A, R&D, Rodeo Therapeutics
0 Comment
Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trial
Richard Staines
Eli Lilly, inflammatory diseases, mirikizumab, ulcerative colitis
0 Comment
BMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitis
Phil Taylor
Bristol-Myers Squibb, fda, inflammatory diseases, ulcerative colitis, Zeposia
0 Comment
GSK suffers another R&D setback, axing ulcerative colitis drug trial
Richard Staines
GlaxoSmithKline, Immutep, inflammatory diseases, ulcerative colitis
0 Comment
AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi
Richard Staines
AbbVie, Humira, inflammatory diseases, psoriatic arthritis, Skyrizi
0 Comment